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Running title:  hSKCa1 channels and tyrosine kinase regulation 
 
Small conductance Ca2+-activated K+ (SKCa) channels are widely distributed in different tissues 
including the brain, pancreatic islets, myocardium, etc., and play an important role in controlling 
electrical activity and cellular functions. However, intracellular signal modulation of SKCa channels 
is not fully understood. The present study was designed to investigate the potential regulation of 
hSKCa1 channels by protein tyrosine kinases (PTKs) in HEK 293 cells expressing hSKCa1 (KCNN1) 
gene using approaches of whole-cell patch voltage-clamp, immunoprecipitation, Western blot, and 
mutagenesis. We found that hSKCa1 current was inhibited by the broad spectrum PTK inhibitor 
genistein, the selective EGFR (epidermal growth factor receptor) kinase inhibitors T25, and AG556, 
but not by the Src-family kinases inhibitor PP2. The inhibitory effect of these PTK inhibitors was 
significantly antagonized by the protein tyrosine phosphatases (PTPs) inhibitor orthovanadate. 
Tyrosine phosphorylation level of hSKCa1 channels was reduced by genistein, T25, or AG556. The 
reduced tyrosine phosphorylation was countered by orthovanadate. Interestingly, the mutant hSKCa1 
channel with Y109F lost the inhibitory response to T25 or AG556, and showed a dramatic reduction 
of tyrosine phosphorylation level and a reduced current density. These results demonstrate the novel 
information that hSKCa1 channels are inhibited by genistein, T25, and AG556 via EGFR tyrosine 
kinase inhibition, which is related to the phosphorylation of Tyr109 in the N-terminus. This effect may 
affect electrical activity and cellular functions in brain, pancreatic islets, and myocardium.  
Key words: Small conductance Ca2+-activated K+ channels; ion channel modulation; protein 
tyrosine phosphorylation; EGFR tyrosine kinase; mutagenesis  
 
Abbreviations:  SKCa channels, small conductance Ca2+-activated potassium channels; PTKs, protein 
tyrosine kinases; PTPs, protein tyrosine phosphatases; HEK 293 cells, human embryonic kidney 293 cells;  
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Introduction 
Small conductance Ca2+-activated potassium 
(SKCa or SK) channels, like 
intermediate-conductance Ca2+-activated 
potassium (IKCa) channels, are 
voltage-independent, activated by 
intracellular free Ca2+, and play an 
 
 
 
important role in regulating many processes 
involving Ca2+-dependent signaling in both 
electrically excitable and nonexcitable cells 
[1, 2]. There are three types of SKCa 
channels, including SKCa1 (SK1), SKCa2 
(SK2) and SKCa3 (SK3) encoded by 
KCNN1, KCNN2, and KCNN3, respectively 
[3]. SKCa channels are expressed in 
different types of tissues/cells including 
various regions of the brain [4, 5], 
pancreatic islets [6], cardiac myocytes [7-9], 
and endothelial cells (for SKCa3) [10], etc.  
Like BKCa channels (large conductance 
Ca2+- and voltage-activated K+ channels) 
[11] and IKCa channels [1], SKCa channels 
are sensitive to intracellular free Ca2+ ions 
[2, 12, 13]. BKCa channels are found to be 
enhanced by protein kinase C (PKC) and/or 
cAMP/protein kinase A (PKA) via 
activating cyclic guanosine monophosphate- 
(cGMP) dependent kinase [14-17]. 
Nonetheless, information for the regulation 
of SKCa channels by intracellular signal 
transduction is not fully understood. Recent 
studies reported that Ca2+-sensitivity of 
SKCa channels was regulated by interaction 
of protein kinase CK2 and protein 
phosphatase 2A [18, 19], and the plasma 
membrane surface expression of SKCa2 
channels was regulated by PKA via 
phosphorylation of serine 568-570 in the C 
terminus of the channel [20]. Activation of 
PKA reduced membrane expression of 
SKCa channels in hippocampal and 
amygdale neurons [21]. 
Protein tyrosine kinases (PTKs), 
including receptor PTKs (e.g. EGFR kinase, 
epidermal growth factor receptor kinase) 
and non-receptor PTKs (e.g. Src-family 
kinases), are important intracellular signals 
[22]. In addition to the modulation of cell 
growth, differentiation, embryonic 
development, metabolism, immune system 
function, oncogenesis etc. [22], PTKs also 
modulate different types of ion channels 
[23], including L-type Ca2+ (ICa.L) channels 
[24], the voltage-gated Na+ (INa) channels 
[25, 26], volume sensitive Cl− (ICl.vol) 
channels [27], as well as voltage-gated K+ 
channels [28-35], and also BKCa channels 
[36]. Currently, the PTK modulation of 
SKCa1 channels is unknown. The present 
study was therefore designed to determine 
whether/how PTKs regulate hSKCa1 
channels stably expressed in HEK 293 cells 
using approaches of electrophysiology, 
immunoprecipitation, Western blotting, and 
mutagenesis. We found that PTK inhibitors 
genistein, T25, and AG556 decreased 
hSKCa1 current by inhibiting EGFR kinase.  
 
Material and Methods  
Cell culture, mutagenesis, and gene 
transfection 
The pCDNA3/hSKCa1 (KCNN1) plasmid 
kindly provided by Dr. Nicole Schmitt 
(University of Copenhagen, Denmark) was 
transfected into HEK 293 cells (ATCC, 
Manassas, VA) using Lipofectamine 2000TM. 
The HEK 293 cell line stably expressing 
hSKCa1 gene was established as previously 
described [31, 32]. The hSKCa1 cell line 
was maintained in Dulbecco’s modified 
eagle’s medium (DMEM, Invitrogen, Hong 
Kong, China) supplemented with 10% fetal 
bovine serum and 400 µg/ml G418 
(Invitrogen). Cells used for 
electrophysiology were cultured on a glass 
cover slip.  
 The predicted potential tyrosine 
phosphorylation sites of hSKCa1 channels 
were examined using the software NetPhos 
2.0 (www.cbs.dtu.dk/cgi-bin). Single amino 
acid substitutions of hSKCa1 were 
generated using a QuikChange II XL 
 
 
 
Site-directed mutagenesis kit (Stratagene, 
La Jolla, CA) following the manufacturer’s 
instruction, and confirmed by DNA 
sequencing. Polymerase chain reaction 
(PCR) was made with hSKCa1 as a template 
and a pair of complementary mutagenesis 
primers. The PCR products were digested 
with Dpn I and then transformed into 
competent cells DH5α for plasmids 
amplification. The three mutants Y109F, 
Y138F and Y406F were generated and 
confirmed by full DNA sequencing. The 
mutants were transiently expressed in HEK 
293 cells with a 35 mm culture dish using 
10 µl of Lipofectamine 2000TM with 4 µg of 
pCDNA3.1/hKv4.3-mutant vector. Cells 
used for electrophysiology were seeded on a 
glass coverslip.   
Solutions and reagents 
Tyrode’s solution contained (mM) NaCl 140, 
KCl 5.4, MgCl2 1.0, CaCl2 1.8, 
4-(2-hydroxyethyl)-1-piperazineethanesulfo
nic acid (HEPES) 10.0 and glucose 10 (pH 
adjusted to 7.3 with NaOH). For whole-cell 
recordings, the pipette solution contained 
(mM) KCl 20, K-aspartate 110, MgCl2 1.0, 
HEPES 10, ethyleneglycoltetraacetic acid 
(EGTA) 5, GTP 0.1, Na-phosphocreatine 5, 
and Mg-ATP 5 (pH adjusted to 7.2 with 
KOH) with including 300 nM free Ca2+ 
(calculated using the Cabuf software 
provided by Dr. G. Droogmans in the 
Department of Physiology, KU Leuven, 
Leuven, Belgium).    
 3-(4-Chlorophenyl)1-(1,1-dimethyl- 
ethyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amin
e (PP2) was purchased from Tocris (Bristol, 
UK). All other reagents were obtained from 
Sigma-Aldrich (St Louis, MO). Stock 
solutions were made with dimethylsulfoxide 
(DMSO) for genistein (100 mM), tyrphostin 
AG 556 (AG556, 100 mM), tyrphostin 25 
(T25, 100 mM), tyrphostin 63 (T63, 100 
mM), and PP2 (30 mM). The stocks were 
divided into aliquots and stored at −20°C. 
Sodium orthovanadate stock solution (200 
mM) was made with distilled water, and pH 
value was adjusted to 9.0. 
Electrophysiology  
Cells on a coverslip were transferred to a 
cell chamber (0.5 ml) mounted on the stage 
of an inverted microscope (Diaphot, Nikon, 
Japan) and superfused at ~2 ml/min with 
Tyrode solution. Whole-cell currents were 
recorded as described previously [31, 32, 
34]. Borosilicate glass electrodes (1.2-mm 
OD) were pulled with a Brown-Flaming 
puller (model P-97, Sutter Instrument Co, 
Novato, CA) and had a resistance of 2–3 
MΩ when filled with the pipette solution. A 
3-M KCl agar bridge was used as the 
reference electrode. The tip potential was 
zeroed before the patch pipette contacted the 
cell. After a gigaohm seal was obtained, the 
cell membrane was ruptured by applying a 
gentle negative pressure to establish the 
whole-cell configuration. Series resistance 
(Rs) was 4-6 MΩ and was compensated by 
50-80% to minimize voltage errors. The 
liquid junction potential (~12 mV) was not 
corrected in the experiment. Membrane 
currents were measured using an EPC-10 
amplifier and Pulse software (Heka 
Elektronik, Lambrecht, Germany). 
Command pulses were generated by a 12-bit 
digital-to-analog converter controlled by 
Pulse software. Current signals were 
low-pass filtered at 5 kHz and stored in the 
hard disk of an IBM compatible computer. 
All experiments were conducted at room 
temperature (22–23 ºC).  
Immunoprecipitation and Western 
blotting  
The immunoprecipitation and Western 
blotting were performed following the 
procedure described previously [32, 34]. 
 
 
 
HEK 293 cells (~80% confluence) stably 
expressing hSKCa1 channels were treated 
respectively with different compounds, e.g. 
genistein, T25, AG556, PP2, orthovanadate, 
epidermal growth factor (EGF), etc. for 30 
min at room temperature, and centrifuged at 
4oC. The cell pellet was then lysed with the 
lysis buffer containing (mM) 25 Tris, 150 
NaCl, 1.0 NaF, 1.0 EDTA, 1.0 
orthovanadate, 1.0 phenylmethylsulfonyl 
fluoride, and 1% Na deoxycholate, 0.1% 
SDS, 1% Triton X-100, 1 µg/ml leupeptin, 
and 1 µg/ml aprotinin. Protein quantification 
of lysates was made using a protein assay 
reader (Bio-Rad Laboratories, Hercules, 
CA), and diluted to equal concentrations. 
Proteins were immunoprecipitated overnight 
at 4°C using 2 µg of goat anti-hSKCa1 
(sc-17991) antibody (Santa Cruz 
Biotechnology, Santa Cruz, CA) and 100 µl 
of protein A/G beads (DAM 1460243, 
Millipore, Billerica, MA). The 
immunoprecipitated proteins bound to 
pelleted protein A/G beads were washed 
thoroughly in PBS, denatured in Laemmli 
sample buffer, separated using SDS-PAGE, 
and electroblotted onto nitrocellulose 
membranes. The immunoblots were probed 
with anti-phosphotyrosine antibody (1:1000, 
Cell Signaling Tech., Danvers, MA) 
overnight at 4°C in a blocking solution 
containing 5% BSA in TBS and Tween 20, 
and subsequently treated with goat 
anti-mouse IgG-HRP antibody (1:5000, 
Santa Cruz Biotechnology) for 2 h at room 
temperature. Blots were developed with 
enhanced chemiluminescence (ECL, 
Amersham Biosciences) and exposed on 
X-ray film (Fuji Photo Film GmbH). The 
blots were then stripped and reprobed with 
the anti-hSKCa1 channel antibody to 
determine total hSKCa1 channel protein. 
The film was scanned, imaged by a 
Bio-Imaging System (Syngene, Cambridge, 
UK), and the intensity of the bands was 
analyzed via GeneTools software (Syngene). 
Statistical analysis  
Experimental group data are expressed as 
means ± SEM. Paired and/or unpaired 
Student’s t-test were used as appropriate to 
evaluate the statistical significance of 
differences between two group means, and 
ANOVA was used for multiple groups. 
Values of P<0.05 were considered to be 
statistically significant. 
 
Results 
SKCa1 current inhibition by apamin in 
HEK 293 cell line 
Figure 1 illustrates the membrane currents 
HEK 293 cells without/with transfecting 
hSKCa1 (KCNN1) gene. Only a small 
background current (Fig. 1A) was recorded 
using a pipette solution containing 300 nM 
free Ca2+ with the voltage steps as shown in 
the inset in a HEK 293 cell without hSKCa1 
gene transfection (n=4), and showed a linear 
I-V relationship when recorded using a 3-s 
ramp from −100 to +80 mV (left panel). 
However, a lager membrane current was 
recorded under the same conditions (as in A) 
in a HEK 293 cell stably expressing 
hSKCa1 gene, and the current was inhibited 
by the SKCa channel blocker apamin [37]. 
I-V relationship curve of the current 
exhibited a weak inward rectification was 
inhibited by 300 nM apamin (Fig. 1C, n=4), 
suggesting a typical of SKCa current.  
Inhibition of hSKCa1 current by 
genistein    
Our previous studies have demonstrated that 
genistein decreases several potassium 
currents via inhibiting PTKs [28, 32, 33]. To 
investigate whether it is the case for 
 
 
 
hSKCa1 channels, genistein (30 µM) was 
tested in HEK 293 cells stably expressing 
hSKCa1 gene. The membrane current 
elicited by 200-ms voltage steps to between 
−70 to +80 mV from a holding potential of 
−80 mV or a 3-s ramp from −100 to +80 mV 
exhibited an inward rectifier property, a 
typical of hSKCa1 current (Fig. 2A and 2B). 
The current was significantly inhibited by 
application of genistein in bath solution (6 
min), and the effect was reversed on 
washout (8 min). Genistin, a glycoside 
derivative (PTK-inactive) compound of 
genistein had no inhibitory effect on 
hSKCa1 current at 30 µM, while 30 µM 
genistein significantly inhibited the current 
in the same cell (Fig. 2B), suggesting that 
PTK inhibition is involved in the current 
reduction by genistein.   
 If the reduction of hSKCa1 current by 
genistein is related to the inhibition of PTKs, 
its effect should be antagonized by the PTP 
inhibitor orthovanadate. Figure 2C shows 
that the hSKCa1 current inhibition by 
genistein was partially reversed by 
co-application of genistein and 
orthovanadate (1 mM). As the observations 
in Kv4.3 [35] and hERG [32] and IKs [28] 
channels, orthovanadate (1 mM) did not 
show any effect on hSKCa1 current (Fig. 
2D). It however, significantly prevented the 
current reduction by genistein. Figure 2E 
illustrates the mean percentage values of 
hSKCa1 current (at +40 mV) in cells treated 
with 30 µM genistein, 30 µM genistin, 1 
mM orthovanadate, genistein plus 
orthovanadate, 1 mM orthovanadate, or 
orthovanadate plus 30 µM genistein. 
Genistein decreased the current to 
59.8±4.6% of control (n=12, P<0.01), and 
the current inhibition was reversed by 
orthovanadate to 74.9±3.4% of control (n=5, 
P<0.05 vs. genistein alone). Genistin and 
orthovanadate had no effect on hSKCa1 
current. Pretreatment with orthovanadate 
significantly prevented the current inhibition 
by genistein (current reduction: by 
11.5±5.5% vs. 25.1±3.4% with genistein 
plus orthovanadate, n=6, P<0.05). The 
results suggest that genistein-induced 
hSKCa1 current reduction is likely related at 
least in part to inhibition of PTKs.  
To further investigate which specific 
PTK is involved in the regulation of 
hSKCa1 channels, the selective Src-family 
kinases inhibitor PP2 [38], and the highly 
selective EGFR kinase inhibitors T25 and 
AG556 [39-41] were tested in the following 
experiments.  
Effect of PP2 on hSKCa1 current 
Figure 3A shows the time course of hSKCa1 
current recorded in a typical experiment 
with a 200-ms voltage step to +40 mV from 
a holding potential of −80 mV in the 
absence and presence of PP2. PP2 (10 µM, 
2000 times higher than IC50 for inhibiting 
Src kinases) [38] had no inhibitory effect on 
hSKCa1 current during 15 min exposure. 
Similarly, step hSKCa1 current and the I-V 
relationships were not affected by the 
application of 10 µM PP2 (Fig. 3B and 3C). 
Mean percentage value of hSKCa1 current 
at +40 mV was not altered by PP2 (10 µM, 
Fig. 3D). These results suggest that hSKCa1 
channels are not regulated by Src-family 
kinases.  
Inhibition of hSKCa1 current by T25 and 
AG556  
Figure 4 shows the effect of the EGFR 
kinase inhibitor T25 on hSKCa1 current. 
Voltage step-activated hSKCa1 current was 
significantly reduced by T25 application in 
bath solution, and the reduction partially 
recovered on washout (Fig. 4A). Figure 4B 
shows the time course of hSKCa1 current 
recorded with a ramp protocol in a 
 
 
 
representative cell. T63 (a PTK-inactive 
analog of tyrphostin) at 30 µM had a slight 
inhibitory effect on hSKCa1 current, while 
T25 at 10 µM induced a significant current 
reduction in the same cell. The current 
inhibition by T25 (10 µM) was partially 
reversed by co-application of T25 and 1 mM 
orthovanadate (Fig. 4C). Pretreatment of the 
cell with orthovanadate significantly 
prevented the current reduction by T25 (Fig. 
4D). The mean percentage values of 
hSKCa1 current ( +40 mV) are illustrated in 
Fig. 4E in cells treated with 10 µM T25, 30 
µM T63, T25 plus 1 mM orthovanadate, 1 
mM orthovanadate, or orthovanadate plus 
10 µM T25. T25 decreased the current to 
60.1±2.9% of control (n=11, P<0.01 vs. 
control) and the inhibition recovered on 
washout to 84.1±5.9% of control (P<0.01 vs. 
T25 alone). The current inhibition was 
antagonized to 82.7±3.9% of control by 
orthovanadate (P<0.01 vs. T25 alone). The 
PTK-inactive analog T63 (30 µM) and 
orthovanadate had no significant inhibition 
of hSKCa1 current (n=6, P=NS vs. control). 
In cells pretreated with orthovanadate, the 
current inhibition by T25 was significantly 
prevented (current inhibition: by 8.0±4.5%, 
n=6, P<0.05 vs. 17.3±3.9% with T25 plus 
orthovanadate). These results indicate that 
T25-induced hSKCa1 current reduction is 
related to the inhibition of EGFR kinase.  
 We have previously demonstrated that 
the highly selective EGFR kinase inhibitor 
AG556 inhibits several K+ channels (e.g. 
hERG, hEAG1, IKs, Kir2.1, and Kir2.3) [28, 
31-34] in a PTK-dependent manner. To 
determine whether it is the case for hSKCa1 
channels, AG556 was tested. Figure 5A 
shows the hSKCa1 current recorded in a 
representative cell during control, AG556 
application, and washout. AG556 (10 µM, 5 
min) inhibited hSKCa1 current and the 
current reduction was partially recovered by 
washout. Figure 5B shows the time-course 
of the step current in the absence and 
presence of 10 µM AG556, and 
co-application of 1 mM orthovanadate. The 
current inhibition by AG556 was partially 
reversed by co-application of AG556 and 
orthovanadate. The pretreatment of the cell 
with orthovanadate also significantly 
prevented the current reduction by AG556 
(Fig. 5C). The mean percentage values of 
hSKCa1 current at +40 mV are illustrated in 
Fig. 5D. The current at +40 mV was reduced 
by AG556 to 62.4±7.8% of control (n=10, 
P<0.01 vs. control), the reduction 
significantly recovered on washout (P<0.01 
vs. AG556 alone). The current inhibition 
was reversed to 78.5±5.7% of control with 
co-application of genistein and 
orthovanadate (P<0.01 vs. AG556 alone). 
The current reduction by AG556, as in 
genistein and T25, significantly prevented in 
cells pretreated with orthovanadate (current 
inhibition: by 9.9±4.5%, n=6, P=0.05 vs. 
21.5±5.5% with AG556 plus orthovanadate). 
These results further support the notion that 
hSKCa1 current is regulated by EGFR 
kinase. 
However, hSKCa1 channels were not 
stimulated by application of the EGFR 
kinase activator EGF (100 ng/ml) in the bath 
solution (n=5, data not shown). This 
suggests that tyrosine phosphorylation of 
hSKCa1 channels, like hERG, IKs, and 
Kir2.1 channels [28, 32, 33], is at a 
saturated state under control conditions.    
Tyrosine phosphorylation level of 
hSKCa1 channels 
To investigate how tyrosine phosphorylation 
of hSKCa1 channels is affected by PTK 
inhibitors, immunoprecipitation and Western 
blot analysis were performed in hSKCa1 
HEK 293 cells. Figure 6A displays the 
images of tyrosine phosphorylation level of 
 
 
 
hSKCa1 channels with different treatments 
(30 min). Tyrosine phosphorylation was 
reduced by the broad spectrum PTK 
inhibitor genistein (30 µM) and the EGFR 
kinase inhibitors AG556 (10 µM) and T25 
(10 µM), but not by the Src-family kinase 
inhibitor PP2 (10 µM), orthovanadate (1 
mM) or EGF (100 ng/ml). The reduced 
phosphorylation level by PTK inhibitors 
was significantly antagonized in cells 
treated with co-application of orthovanadate 
(1 mM). Figure 6B illustrates the mean 
percentage values of tyrosine 
phosphorylation in cells with different 
treatments. PP2, orthovanadate, and EGF 
had no effect on the phosphorylation level. 
Tyrosine phosphorylation was reduced to 
59.8±6.9% by genistein (P<0.01 vs. vehicle), 
to 46.2±6.7% by AG556 (P<0.01 vs. 
vehicle), and to 53.7±5.7% by T25 (P<0.01 
vs. vehicle). The reduced phosphorylation 
was reversed to 84.7 ± 10.1% by 
orthovanadate plus genistein (P<0.05 vs 
genistein alone), 86.7±8.5% by 
orthovanadate plus AG556 (P<0.05 vs. 
AG556 alone), and to 85.7±4.5% by 
orthovanadate plus T25 (P<0.05 vs. T25 
alone). These results demonstrate that the 
tyrosine phosphorylation level is affected by 
PTK inhibitors genistein, AG556 and 
tyrphostin 25 (but not PP2), and their 
interactions can be countered with the PTP 
inhibitor orthovanadate. No alteration of 
tyrosine phosphorylation of hSKCa1 
channel protein with application of EGF or 
orthovanadate implicates a saturated 
phosphorylation state of the channel.    
Tyrosine phosphorylation sites of hSKCa1 
channels 
To investigate the potential tyrosine 
phosphorylation sites of hSKCa1 channels, 
three mutant channels (Y109F, Y138F and 
Y406F) were generated using phenylalanine 
to substitute for tyrosine. The inhibitory 
response of these mutants to PTK inhibitors 
was determined with the selective EGFR 
kinase inhibitors T25 and AG556. Figure 7A 
shows the hSKCa1 mutant currents in the 
absence and presence of 10 µM T25. T25 
significantly inhibited Y138F and Y406F 
currents, but exhibited only a slight 
inhibition of Y109F current. Interestingly, 
AG556 also only slightly reduced Y109F 
current, while suppressed Y138F and Y406F 
currents (Fig. 7B). The mean percentage 
values of WT and mutant hSKCa1 channels 
inhibition by T25 or AG556 are illustrated 
in Fig. 7C. T25 (10 µM) and AG556 (10 µM) 
inhibited hSKCa1 Y109F current (at +40 
mV) by 9.1±2.9% (n=5, P<0.05 vs. control) 
and 10.3±1.5% (n=6, P<0.05 vs. control). 
The inhibitory effect of these two EGFR 
kinase inhibitors on WT, Y138F, and Y406F 
was stronger than that on Y109F current 
(P<0.01 vs. WT, Y138F or Y406F). These 
results suggest that tyrosine phosphorylation 
site of hSKCa1 channels is likely located at 
Y109 residue of the N-terminus.      
If the Y109 of hSKCa1 channels is 
responsible for tyrosine phosphorylation, the 
phosphorylation should be reduced in the 
mutant channels with Y109F. To determine 
whether it is the case, immunoprecipation 
and Western blot analysis were employed in 
HEK 293 cells expressing Y109F mutant or 
WT hSKCa1 channels. Figure 8A shows the 
tyrosine phosphorylation levels in HEK 293 
cells expressing WT or Y109F hSKCa1 
channels with or without 10 µM AG556 
treatment. Tyrosine phosphorylation level 
was evident in WT hSKCa1 channels, which 
was significantly reduced by AG556. 
However, the phosphorylation was 
dramatically reduced in Y109F hSKCa1 
channels. The results obtained in the present 
study demonstrated that the reduction of 
hSKCa1 current by the PTK inhibitors 
genistein, T25, and AG556 were related to 
 
 
 
the inhibition of EGFR kinase and the 
decrease of tyrosine phosphorylation at 
Y109 of hSKCa1 channels. Orthovanadate 
inhibits PTPs thereby antagonizes the PTK 
inhibitors-induced reduction of the current 
amplitude and tyrosine phosphorylation of 
hSKCa1 channels (Fig. 8B). The current 
density was significantly reduced in cells 
expressing the mutant Y109F hSKCa1 
channels (Fig. 8C and 8D), suggesting that 
tyrosine phosphorylation of hSKCa1 
channels at Y109 plays an important role in 
regulation of  the channel activity.  
 
Discussion  
In the present study, we have shown that 
inhibition of EGFR kinase by genistein, T25, 
and AG556 reduces hSKCa1 channels stably 
expressed in HEK 293 cells. Tyrosine 
phosphorylation level of hSKCa1 channels 
is decreased by genistein, T25, or AG556. 
Their inhibitory effects on hSKCa1 current 
and tyrosine phosphorylation are 
antagonized by the PTP inhibitor 
orthovanadate. Site-directed mutagenesis 
reveals that Y109 residue is the 
phosphorylation site of the channel by 
EGFR kinase. 
 Previous studies have demonstrated 
that PTKs regulate different ion channels, 
including ICa.L channels [24], INa channels 
[25, 26], and ICl.vol channels [20, 27] in 
mammalian heart myocytes, as well as 
several types of K+ channels in different 
types of cells [23, 28, 30-35], and also 
TRPC6 channels [42]. Both EGFR kinase 
and Src-family kinases participate in 
regulating cardiac ICl.vol [20, 27], INa 
channels [25, 26], Kv4.3 channels [35], and 
hERG channels [32], whereas Src-family 
kinases are not involved in modulation of 
cardiac slowly-delayed rectifier K+ channel 
current (IKs) [28], the inwardly-rectifier K+ 
channels (Kir2.1 and Kir2.3) [33, 34], and 
hEAG1 channels [31]. The present study 
provided the novel information that hSKCa1 
channels stably expressed in HEK 293 cells 
are regulated by EGFR kinase, but not by 
Src-family kinases.  
 Using multiple experimental 
techniques including electrophysiology, 
immunoprecipitation, Western blot analysis, 
and mutagenesis, we found that hSKCa1 
current was reduced by the broad spectrum 
PTK inhibitor genistein and the selective 
EGFR kinase inhibitors T25 and AG556 via 
inhibiting PTKs. Four lines of evidence 
support the conclusion that EGFR kinase 
regulates hSKCa1 channels. First, T63, an 
inactive analog of tyrphostins, respectively, 
did not have any meaningful effect on 
hSKCa1 channels. Second, as expected for 
phosphorylation-dependent processes, 
inhibition of PTPs by orthovanadate 
antagonized the current reduction by PTK 
inhibitors. Third, tyrosine phosphorylation 
level of hSKCa1 channels was reduced by 
genistein, T25, and AG556, and the 
reduction was reversed by orthovanadate. 
Finally, the mutant Y109F hSKCa1 channels 
exhibited a weak inhibitory response to the 
EGFR kinase inhibitors T25 and AG556, a 
reduced tyrosine phosphorylation.  Also 
the mutant channels showed a decreased 
current density. Moreover, the the 
Src-family kinase inhibitor PP2 did not alter 
hSKCa1 channel current or the tyrosine 
phosphorylation level, indicating that 
Src-family kinases are not involved in PTK 
regulation of hSKCa1 channels. This is 
consistent with IKs, hEAG1, Kir2.1 and 
Kir2.3 channels [28, 30, 31, 33, 34], which 
are regulated by EGFR kinase, but not by 
Src-family kinases.   
 Earlier studies have demonstrated that 
SKCa channels (SKCa1, 2, 3) are expressed 
 
 
 
in the brain [43]. In addition controlling 
dendritic integration, synaptic transmission, 
and synaptic plasticity, SKCa channels play 
a role in regulating learning and memory 
[43-45].  SKCa channels are also present in 
pancreatic islets and regulate glucose 
response of β-cells [6]. It has been reported 
in rat insulinoma cell line (INS-1) that 
SKCa1 channels are responsible for a more 
negative resting membrane potential, 
regulate the duration of action potentials, 
and therefore control insulin secretion. 
Silencing SKCa1 channels with KCNN1 
siRNA results in a more depolarized resting 
membrane potential and increases insulin 
secretion [46]. Moreover, recent studies 
have reported that SKCa channels are 
expressed predominantly in atrial myocytes 
of the heart [7-9]. Therefore, SKCa channels 
are believed to be a potential target for the 
study of anti-atrial fibrillation [47, 48].  
 In the present study, we demonstrated 
that hSKCa1 channel activity was decreased 
by EGFR kinase inhibition. We therefore 
speculate that tyrosine phosphorylation of 
SKCa channels by EGFR kinase may be 
important in controlling electrical activity in 
neuronal cells, islet β-cells, and cardiac 
atrial myocytes. If it is the case, inhibition 
of EGFR kinase by genistein, T25, and 
AG556 would affect the dentritic integration 
and excitability, synaptic transmission and 
synaptic plasticity in the brain, insulin 
release in the β-cells, and would also show 
some anti-atrial fibrillation effects. However, 
these remain to be demonstrated in future 
experimental study in different systems.   
 In addition to the requirement of 
additional series of experiments to 
demonstrate potential physiological roles of 
EGFR kinase regulation on hSKCa1 
channels, another limitation of the present 
study is that we are unable to demonstrate 
the stimulatory effect on hSKCa1 channels 
with orthovanadate or EGF. We have 
previously shown that the inhibition of PTPs 
with orthovanadate or EGFR activation with 
EGF increased current amplitude and 
tyrosine phosphorylation levels in Kir2.3 
channels [34] and cardiac INa [25]. However, 
no effect was observed on hSKCa1 current 
or tyrosine phosphorylation with 
orthovanadate or EGF in the present study. 
One possible interpretation is that tyrosine 
phosphorylation is already saturated, 
therefore no additional increase of current 
amplitude and phosphorylation level can be 
observed by inhibiting PTPs or activating 
EGFR kinase. Saturated tyrosine 
phosphorylation was also observed in hERG 
[32], hEAG1 [31], IKs [28], Kir2.1 channels 
[33], and hKv4.3 channels [35], and 
therefore stimulation of EGFR kinase with 
EGF or inhibition of dephosphorylation with 
orthovanadate does not increase the current 
amplitude or tyrosine phosphorylation level 
of these channels. 
 In summary, the present study has 
provided the first evidence that the PTK 
inhibitors genistein, T25, and AG556 
decrease hSKCa1 channels stably expressed 
in HEK 293 cells via inhibiting EGFR 
kinase that is related to phosphorylation of 
Y109 residue of the channel in the 
N-terminus. This effect may affect cellular 
electrical activity and thus modulate cellular 
functions in mammalian related 
organs/tissues including brain, islets and 
hearts. 
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Figure 1. Apamin inhibits the membrane current in HEK 293 cells expressing hSKCa1 channels. A. 
Only a small background current was recorded with the voltage steps as shown in the inset in a 
HEK 293 cell without hSKCa1 gene transfection with a pipette solution containing 300 nM free 
Ca2+ (n=3), showing a linear I-V relationship of a 3-s ramp voltage protocol from −100 to +80 
mV (left panel). B. Representative current was recorded with same the protocol as in panel A in 
a HEK 293 cell stably expressing hSKCa1 gene in the absence and presence of 300 nM apamin. 
C. I-V relationship curves of the ramp current recorded in the same cell as in B in the absence 
and presence of apamin (n=4). Arrows indicate zero current level. 
 
 
 
 
 
 
 
Figure 2. Effect of genistein on hSKCa1 current. A. hSKCa1 current recorded in a representative cell 
with 200-ms voltage steps between −70 and +80 mV from a holding potential of −80 mV (inset) 
in the absence (control) and presence of 30 µM genistein, and upon washout. B. Time-course of 
hSKCa current recorded in a typical experiment with a 3-s ramp (-100 to +80 mV) from a 
holding potential -80 mV in the absence and presence of 30 µM genistin or 30 µM genistein. 
The current was measured at -100 and +40 mV. The original ramp I-V current traces at 
corresponding time points are shown in right of the panel. C. hSKCa1 current recorded in a 
representative cell during control, in the presence of 30 µM genistein, and genistein plus 1 mM 
orthovanadate (OV). D. hSKCa1 current recorded in a representative cell during control, in the 
presence of 1 mM orthovanadate, and orthovanadate plus 30 µM genistein. E. Mean percentage 
values of hSKCa1 current at +40 mV during control, 30 µM genistein, washout, 30 µM genistin, 
genistein plus 1 mM orthovanadate. 1 mM orthovanadate, or orthovanadate plus 30 µM 
genistein (n=5-8, *P<0.05, **P<0.01 vs. control; #P<0.05; ##P<0.01 vs. genistein alone; 
$P<0.05 vs. genistein plus orthovanadate). The arrows indicate the zero level.  
 
 
 
 
 
 
Figure 3. Effect of PP2 on hSKCa1 current. A. Time-course of hSKCa1 current recorded in a 
representative cell with a 200-ms voltage step to +40 mV from a holding potential of -80 mV 
(inset) in the absence and presence of 10 µM PP2. Original current traces at corresponding time 
points are shown in right of the panel. B. hSKCa1 current recorded in a typical experiment in 
the absence and presence of 10 µM PP2. The arrow indicates the zero level. C. I-V relationship 
traces recorded in another cell with a ramp voltage protocol as described in Fig. 1B in the 
absence and presence of 10 µM PP2. D. Mean percentage values of hSKCa1 current in the 
absence (control) and presence of 10 µM PP2 (n=5, P=NS vs. control).  
 
 
 
 
 
 
 
Figure 4.  Effect of tyrphostin 63 (T63) and tyrphostin 25 (T25) on hSKCa1 current. A. hSKCa1 
recorded in a representative cell in the absence and presence of 10 µM T25.  B. Time-course of 
hSKCa current recorded in a typical experiment with a 3-s ramp (-100 to +80 mV) from a holding 
potential -80 mV in the absence and presence of 30 µM T63 or 30 µM T25. The current was measured 
at -100 and +40 mV. The original ramp I-V current traces at corresponding time points are shown in 
right of the panel. C. hSKCa1 current recorded in a representative cell during control, in the presence 
of 10 µM T25, and T25 plus 1 mM orthovanadate (OV). D. hSKCa1 current recorded in another 
representative cell during control, in the presence of 1 mM orthovanadate, and orthovanadate plus 10 
µM T25. E. Mean percentage values of hSKCa1 current at +40 mV during control, 10 µM T25, 
washout, 30 µM T63, T25 plus 1 mM orthovanadate, 1 mM orthovanadate, or orthovanadate plus 10 
µM T25 (n=5-8, *P<0.05, **P<0.01 vs. control; #P<0.05; ##P<0.01 vs. T25 alone; $P<0.05 vs. T25 
plus orthovanadate). 
 
 
 
 
 
 
Figure 5. Effect of AG556 on hSKCa1 current.  A. hSKCa1 current recorded in a representative cell 
in the absence and presence of 10 µM AG556, and washout. B. Time-course of step hSKCa1 
current (+40 mV) recorded in a typical of experiment in the absence and presence of 10 µM 
AG556, and AG556 plus 1 mM orthovanadate (OV). Original current traces at corresponding 
time points are shown in right of the panel. C. hSKCa1 current recorded in another 
representative cell during control, in the presence of 1 mM orthovanadate, and orthovanadate 
plus 10 µM AG556. D. Mean percentage values of hSKCa1 current at +40 mV before (control) 
and after application of 10 µM AG556, washout, AG556 plus orthovanadate, 1 mM 
orthovanadate, orthovanadate plus  10 µM AG556 (n=6, **P<0.01 vs. control, ##P<0.01 vs. 
AG556 alone). 
 
 
 
 
 
 
Figure 6. Tyrosine phosphorylation levels of hSKCa1 channels. A. Images of immunoprecipitation 
and Western blotting in cells treated with vehicle, 1 mM orthovanadate (OV), 30 µM genistein, 
10 µM AG556, 10 µM T25, or genistein, AG556, T25 plus 1 mM orthovanadate, or 100 ng/ml 
EGF. B. Mean percentage values of relative tyrosine-phosphorylated hSKCa1 channel protein. 
The amount of protein from the immunoprecipitation (as shown in A) was normalized to those 
from the Western blots. Relative phosphorylated protein level (n=4-7 experiments) is expressed 
as a percentage of vehicle control. **P<0.01 vs. control, #P<0.05 vs. genistein, AG556 or T25 
alone.  
 
 
 
 
 
Figure 7. Effects of T25 and AG556 on mutant hSKCa1 channels.  A. hSKCa1 currents recorded in 
representative cells expressing Y109F, Y138F or Y406F mutant in the absence (control) and 
presence of 10 µM T25.  B. hSKCa1 currents recorded in cells expressing Y109F, Y138F and 
Y406F mutants in the absence and presence of 10 µM AG556. C. Left panel: mean percentage 
values of hSKCa1 current at +40 mV in cells expressing WT (n=12), Y109F (n=5), Y138F (n=5) 
and Y406F (n=5) mutants in the absence (control) and presence of 10 µM T25 (*P<0.05, 
**P<0.01 vs control; #P<0.05 vs. WT, Y138F or Y406F). Right panel: mean percentage values 
of hSKCa1 current at +40 mV in cells expressing WT (n=11), Y109F (n=6), Y138F (n=6) and 
Y406F (n=6) mutants in the absence (control) and presence of 10 µM AG556 (*P<0.05, 
**P<0.01 vs. control; #P<0.05 vs. WT, Y138F or Y406F).  
 
 
 
 
 
Figure 8. Tyrosine phosphorylation levels of Y109F mutant and schematic model for hSKCa1 
modulation. A. Tyrosine phosphorylation was dramatically reduced in cells expressing Y109F 
mutant hSKCa1 gene, but not in WT hSKCa1 channels which show significant inhibitory 
response to 10 µM AG556 (n=3, **P<0.01 vs. WT).  B. Tyrosine residue (Tyr109) of hSKCa1 
channel in the N-terminus is phosphorylated by EGFR kinase and dephosphorylated by PTPs. 
Genistein, T25, or AG556 inhibit EGFR kinase, and therefore reduce the phosphorylation. 
Orthovanadate inhibits PTPs and antagonizes the inhibition of PTK inhibitors. C. Membrane 
current recorded in a HEK 293 cell expressing WT hSKCa1 channels and a HEK 293 cell 
expressing the mutant Y109F hSKCa1 channels. D. I-V relationships of WT hSKCa1 current 
(n=21) and Y109F hSKCa1 current (n=18).       
 
 
